Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations

References

• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-422. doi:10.1056/NEJMoa1001294. PMID:20818862
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780-88. doi:10.1200/JCO.2014.58.3377. PMID:26014293
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der MEIJDEN AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964-70. doi:10.1016/S0022-5347(05)64273-5. PMID:12394686
   PubMed Web of Science ®Google Scholar
• Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: Independent or interdependent processes? Curr Opin Immunol. 2007;19(2):203-208. doi:10.1016/j.coi.2007.02.001. PMID:17292599
   PubMed Web of Science ®Google Scholar
• Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012;482(7385):400-404. doi:10.1038/nature10755. PMID:22318521
   PubMed Web of Science ®Google Scholar
• Schlom J. Therapeutic cancer vaccines: Current status and moving forward. J Natl Cancer Inst. 2012;104(8):599-613. doi:10.1093/jnci/djs033. PMID:22395641
   PubMed Web of Science ®Google Scholar
• Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW, Farsaci B, Madan RA, Heery CR, Gulley JL. Therapeutic cancer vaccines. Adv Cancer Res. 2014;121:67-124. doi:10.1016/B978-0-12-800249-0.00002-0. PMID:24889529
   PubMed Web of Science ®Google Scholar
• Peres Le P, da Luz FA, Pultz Bo A, Brígido PC, de Araújo RA, Goulart LR, Silva MJ. Peptide vaccines in breast cancer: The immunological basis for clinical response. Biotechnol Adv. 2015;33(8):1868-77. doi:10.1016/j.biotechadv.2015.10.013. PMID:26523780
   PubMed Web of Science ®Google Scholar
• Slingluff CL. The present and future of peptide vaccines for cancer: Single or multiple, long or short, alone or in combination? Cancer J. 2011;17(5):343-350. doi:10.1097/PPO.0b013e318233e5b2. PMID:21952285
   PubMed Web of Science ®Google Scholar
• Hatem S. Developing an effective breast cancer vaccine. Cancer Control. 2010;17(3):183-190. PMID:20664516
   PubMed Web of Science ®Google Scholar
• Emens LA, Jaffee EM. Toward a breast cancer vaccine: Work in progress. Oncology (Williston Park). 2003;17(9):1200-11; discussion 1214, 1217-1208. PMID:14569849
   PubMedGoogle Scholar
• Bolhassani A, Zahedifard F. Therapeutic live vaccines as a potential anticancer strategy. Int J Cancer. 2012;131(8):1733-43. doi:10.1002/ijc.27640. PMID:22610886
   PubMed Web of Science ®Google Scholar
• Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA Jr, Sullivan J, Sarosdy MF, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991;325(17):1205-09. doi:10.1056/NEJM199110243251703. PMID:1922207
   PubMed Web of Science ®Google Scholar
• GuhaThakurta D, Sheikh NA, Fan LQ, Kandadi H, Meagher TC, Hall SJ, Kantoff PW, Higano CS, Small EJ, Gardner TA, et al. Humoral immune response against nontargeted tumor antigens after treatment with sipuleucel-T and its association with improved clinical outcome. Clin Cancer Res. 2015;21(16):3619-30. doi:10.1158/1078-0432.CCR-14-2334. PMID:25649018
   PubMed Web of Science ®Google Scholar
• Sheikh NA, Petrylak D, Kantoff PW, Dela Rosa C, Stewart FP, Kuan LY, Whitmore JB, Trager JB, Poehlein CH, Frohlich MW, et al. Sipuleucel-T immune parameters correlate with survival: An analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother. 2013;62(1):137-147. doi:10.1007/s00262-012-1317-2. PMID:22865266
   PubMed Web of Science ®Google Scholar
• Kohlhapp FJ, Kaufman HL. Molecular pathways: Mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy. Clin Cancer Res. 2016;22(5):1048-54. doi:10.1158/1078-0432.CCR-15-2667. PMID:26719429
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, et al. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15(17):5323-37. doi:10.1158/1078-0432.CCR-09-0737. PMID:19723653
   PubMed Web of Science ®Google Scholar
• Cloosen S, Arnold J, Thio M, Bos GM, Kyewski B, Germeraad WT. Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: Implications for self-tolerance and tumor therapy. Cancer Res. 2007;67(8):3919-26. doi:10.1158/0008-5472.CAN-06-2112. PMID:17440107
   PubMed Web of Science ®Google Scholar
• Gulley JL, Madan RA, Tsang KY, Jochems C, Marté JL, Farsaci B, Tucker JA, Hodge JW, Liewehr DJ, Steinberg SM, et al. Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol Res. 2014;2(2):133-141. doi:10.1158/2326-6066.CIR-13-0108. PMID:24778277
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(7):1099-1105. doi:10.1200/JCO.2009.25.0597. PMID:20100959
   PubMed Web of Science ®Google Scholar
• Schneble EJ, Berry JS, Trappey FA, Clifton GT, Ponniah S, Mittendorf E, Peoples GE. The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: Correlation of immunologic data with clinical response. Immunotherapy. 2014;6(5):519-531. doi:10.2217/imt.14.22. PMID:24896623
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Clifton GT, Holmes JP, Schneble E, van Echo D, Ponniah S, Peoples GE. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol. 2014;25(9):1735-42. doi:10.1093/annonc/mdu211. PMID:24907636
   PubMed Web of Science ®Google Scholar
• Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov. 2017;7(3):264-276. doi:10.1158/2159-8290.CD-16-0828. PMID:28031159
   PubMed Web of Science ®Google Scholar
• Verdegaal EM, de Miranda NF, Visser M, Harryvan T, van Buuren MM, Andersen RS, Hadrup SR, van der Minne CE, Schotte R, Spits H, et al. Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature. 2016;536(7614):91-95. doi:10.1038/nature18945. PMID:27350335
   PubMed Web of Science ®Google Scholar
• Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014;515(7528):572-576. doi:10.1038/nature14001. PMID:25428506
   PubMed Web of Science ®Google Scholar
• Dillman RO. Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors? Hum Vaccin Immunother. 2017;13(3):528-532. doi:10.1080/21645515.2016.1244149. PMID:27808593
   PubMed Web of Science ®Google Scholar
• Finke LH, Wentworth K, Blumenstein B, Rudolph NS, Levitsky H, Hoos A. Lessons from randomized phase III studies with active cancer immunotherapies–outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine. 2007;25(Suppl 2):B97-B109. doi:10.1016/j.vaccine.2007.06.067. PMID:17916465
   PubMed Web of Science ®Google Scholar
• Hanna MG. Cancer vaccines: Are we there yet? Hum Vaccin Immunother. 2012;8(8):1161-65. doi:10.4161/hv.21660. PMID:22854657
   PubMed Web of Science ®Google Scholar
• Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget. 2014;5(2):403-416. doi:10.18632/oncotarget.1719. PMID:24480782
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang KY, Yokokawa J, Hodge JW, Ménard C, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res. 2005;11(9):3353-62. doi:10.1158/1078-0432.CCR-04-2062. PMID:15867235
   PubMed Web of Science ®Google Scholar
• Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, Gameiro SR. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer. 2013;133(3):624-636. doi:10.1002/ijc.28070. PMID:23364915
   PubMed Web of Science ®Google Scholar
• Yu TW, Chueh HY, Tsai CC, Lin CT, Qiu JT. Novel GM-CSF-based vaccines: One small step in GM-CSF gene optimization, one giant leap for human vaccines. Hum Vaccin Immunother. 2016;12(12):3020-28. doi:10.1080/21645515.2016.1221551. PMID:27560197
   PubMed Web of Science ®Google Scholar
• Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev. 2002;188:147-154. doi:10.1034/j.1600-065X.2002.18813.x. PMID:12445288
   PubMed Web of Science ®Google Scholar
• Shi Y, Liu CH, Roberts AI, Das J, Xu G, Ren G, Zhang Y, Zhang L, Yuan ZR, Tan HS, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: What we do and don't know. Cell Res. 2006;16(2):126-133. doi:10.1038/sj.cr.7310017. PMID:16474424
   PubMed Web of Science ®Google Scholar
• Gomez-Cambronero J, Horn J, Paul CC, Baumann MA. Granulocyte-macrophage colony-stimulating factor is a chemoattractant cytokine for human neutrophils: Involvement of the ribosomal p70 S6 kinase signaling pathway. J Immunol. 2003;171(12):6846-55. doi:10.4049/jimmunol.171.12.6846. PMID:14662891
   PubMed Web of Science ®Google Scholar
• Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C, Geilich M, Winkels G, Traggiai E, Casati A, et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol. 2010;40(1):22-35. doi:10.1002/eji.200939903. PMID:19941314
   PubMed Web of Science ®Google Scholar
• Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res. 2007;13(18 Pt 1):5243-48. PMID:17875751
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, Jones JL, Poole DJ, Higgins JP, Hodge JW, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother. 2010;59(5):663-674. PMID:19890632
   PubMed Web of Science ®Google Scholar
• Slingluff CL, Petroni GR, Olson WC, Smolkin ME, Ross MI, Haas NB, Grosh WW, Boisvert ME, Kirkwood JM, Chianese-Bullock KA. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: Outcome of a multicenter randomized trial. Clin Cancer Res. 2009;15(22):7036-44. PMID:19903780
   PubMed Web of Science ®Google Scholar
• Heery CR, Ibrahim NK, Arlen PM, Mohebtash M, Murray JL, Koenig K, Madan RA, McMahon S, Marté JL, Steinberg SM, et al. Docetaxel alone or in combination with a therapeutic cancer vaccine (PANVAC) in patients with metastatic breast cancer: A randomized clinical trial. JAMA Oncol. 2015;1(8):1087-95. PMID:26291768
   PubMed Web of Science ®Google Scholar
• Lawson DH, Lee S, Zhao F, Tarhini AA, Margolin KA, Ernstoff MS, Atkins MB, Cohen GI, Whiteside TL, Butterfield LH, et al. Randomized, placebo-controlled, phase III trial of yeast-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) versus peptide vaccination versus GM-CSF plus peptide vaccination versus placebo in patients with no evidence of disease after complete surgical resection of locally advanced and/or stage IV melanoma: A trial of the eastern cooperative oncology group-American college of radiology imaging network cancer research group (E4697). J Clin Oncol. 2015;33(34):4066-76. PMID:26351350
   PubMed Web of Science ®Google Scholar
• Hoeller C, Michielin O, Ascierto PA, Szabo Z, Blank CU. Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma. Cancer Immunol Immunother. 2016;65(9):1015-34. PMID:27372293
   PubMed Web of Science ®Google Scholar
• Liao W, Lin JX, Leonard WJ. IL-2 family cytokines: New insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol. 2011;23(5):598-604. PMID:21889323
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105-16. PMID:10561265
   PubMed Web of Science ®Google Scholar
• McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23(1):133-141. PMID:15625368
   PubMed Web of Science ®Google Scholar
• FDA. Proleukin (Aldesleukin) drug label. 2012; https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103293s5130lbl.pdf. Accessed April 24, 2017.
   Google Scholar
• Baek S, Kim CS, Kim SB, Kim YM, Kwon SW, Kim Y, Kim H, Lee H. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: Results from a phase I/II trial. J Transl Med. 2011;9:178. doi:10.1186/1479-5876-9-178. PMID:22013914
   PubMed Web of Science ®Google Scholar
• Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364(22):2119-27. doi:10.1056/NEJMoa1012863. PMID:21631324
   PubMed Web of Science ®Google Scholar
• Pathangey LB, McCurry DB, Gendler SJ, Dominguez AL, Gorman JE, Pathangey G, Mihalik LA, Dang Y, Disis ML, Cohen PA. Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens. Oncotarget. 2017;8(7):10785-808. PMID:27974697
   PubMed Web of Science ®Google Scholar
• Li MO, Flavell RA. TGF-beta: A master of all T cell trades. Cell. 2008;134(3):392-404. doi:10.1016/j.cell.2008.07.025. PMID:18692464
   PubMed Web of Science ®Google Scholar
• Bierie B, Moses HL. Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev. 2010;21(1):49-59. doi:10.1016/j.cytogfr.2009.11.008. PMID:20018551
   PubMed Web of Science ®Google Scholar
• Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G, Soares K, Solt S, Dorman A, Wamwea A, Yager A, et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res. 2014;2(7):616-631. doi:10.1158/2326-6066.CIR-14-0027. PMID:24942756
   PubMed Web of Science ®Google Scholar
• de Gramont A, Faivre S, Raymond E. Novel TGF-β inhibitors ready for prime time in onco-immunology. Oncoimmunology. 2017;6(1):e1257453. doi:10.1080/2162402X.2016.1257453. PMID:28197376
   PubMed Web of Science ®Google Scholar
• Faivre SJ, Santoro A, Gane E, et al. A phase 2 study of galunisertib, a novel transforming growth factor-beta (TGF-β) receptor I kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC) and low serum alpha fetoprotein (AFP). Paper presented at: ASCO2016; Chicago, IL.
   Google Scholar
• Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, Hodge JW. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol. 2003;170(12):6338-47. doi:10.4049/jimmunol.170.12.6338. PMID:12794167
   PubMed Web of Science ®Google Scholar
• Ferrara TA, Hodge JW, Gulley JL. Combining radiation and immunotherapy for synergistic antitumor therapy. Curr Opin Mol Ther. 2009;11(1):37-42. PMID:19169958
   PubMedGoogle Scholar
• Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res. 2004;64(12):4328-37. doi:10.1158/0008-5472.CAN-04-0073. PMID:15205348
   PubMed Web of Science ®Google Scholar
• Kudo-Saito C, Schlom J, Camphausen K, Coleman CN, Hodge JW. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin Cancer Res. 2005;11(12):4533-44. doi:10.1158/1078-0432.CCR-04-2237. PMID:15958639
   PubMed Web of Science ®Google Scholar
• Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 2004;64(21):7985-94. doi:10.1158/0008-5472.CAN-04-1525. PMID:15520206
   PubMed Web of Science ®Google Scholar
• Chakraborty M, Wansley EK, Carrasquillo JA, Yu S, Paik CH, Camphausen K, Becker MD, Goeckeler WF, Schlom J, Hodge JW. The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing. Clin Cancer Res. 2008;14(13):4241-49. doi:10.1158/1078-0432.CCR-08-0335. PMID:18594006
   PubMed Web of Science ®Google Scholar
• Gajewski TF. The next hurdle in cancer immunotherapy: Overcoming the non-T-cell-inflamed tumor microenvironment. Semin Oncol. 2015;42(4):663-671. doi:10.1053/j.seminoncol.2015.05.011. PMID:26320069
   PubMed Web of Science ®Google Scholar
• Malamas AS, Gameiro SR, Knudson KM, Hodge JW. Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas' sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation. Oncotarget. 2016;7(52):86937-947. PMID:27893426
   PubMed Web of Science ®Google Scholar
• Stamell EF, Wolchok JD, Gnjatic S, Lee NY, Brownell I. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys. 2013;85(2):293-295. doi:10.1016/j.ijrobp.2012.03.017. PMID:22560555
   PubMed Web of Science ®Google Scholar
• Okuma K, Yamashita H, Niibe Y, Hayakawa K, Nakagawa K. Abscopal effect of radiation on lung metastases of hepatocellular carcinoma: A case report. J Med Case Rep. 2011;5:111. doi:10.1186/1752-1947-5-111. PMID:21418591
   PubMedGoogle Scholar
• Nakanishi M, Chuma M, Hige S, Asaka M. Abscopal effect on hepatocellular carcinoma. Am J Gastroenterol. 2008;103(5):1320-21. doi:10.1111/j.1572-0241.2007.01782_13.x. PMID:18477367
   PubMed Web of Science ®Google Scholar
• Wersäll PJ, Blomgren H, Pisa P, Lax I, Kälkner KM, Svedman C. Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol. 2006;45(4):493-497. doi:10.1080/02841860600604611. PMID:16760190
   PubMed Web of Science ®Google Scholar
• Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V, Giugliano FM, Sandomenico F, Petrillo A, Curvietto M, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology. 2014;3:e28780. doi:10.4161/onci.28780. PMID:25083318
   PubMed Web of Science ®Google Scholar
• Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res. 2013;1(6):365-372. doi:10.1158/2326-6066.CIR-13-0115. PMID:24563870
   PubMed Web of Science ®Google Scholar
• Sebastian M, Papachristofilou A, Weiss C, Früh M, Cathomas R, Hilbe W, Wehler T, Rippin G, Koch SD, Scheel B, et al. Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive(R)) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer. 2014;14:748. doi:10.1186/1471-2407-14-748. PMID:25288198
   PubMed Web of Science ®Google Scholar
• Sebastian M, Klinkhardt U. Phase Ib trial of the RNActive cancer vaccine BI 1361849 (CV9202) and local radiotherapy (RT) in patients (pts) with stage IV NSCLC with disease control after 1st-line chemotherapy or during therapy with an EGFR-TKI: results of an interim analysis. J Clin Oncol. 2016;34(Suppl): Abstract e20627.
   Google Scholar
• Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995;1(9):938-943. doi:10.1038/nm0995-938. PMID:7585221
   PubMed Web of Science ®Google Scholar
• Markert JM, Razdan SN, Kuo HC, Cantor A, Knoll A, Karrasch M, Nabors LB, Markiewicz M, Agee BS, Coleman JM, et al. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther. 2014;22(5):1048-55. doi:10.1038/mt.2014.22. PMID:24572293
   PubMed Web of Science ®Google Scholar
• Whisenhunt TR, Rajneesh KF, Hackney JR, Markert JM. Extended disease-free interval of 6 years in a recurrent glioblastoma multiforme patient treated with G207 oncolytic viral therapy. Oncolytic Virother. 2015;4:33-38. PMID:27512668
   PubMed Web of Science ®Google Scholar
• Mesnil M, Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: Role of gap-junctional intercellular communication. Cancer Res. 2000;60(15):3989-99. PMID:10945596
   PubMed Web of Science ®Google Scholar
• Heery CR, Madan RA, Bilusic M, Singh NK, Rauckhorst M, Steinberg SM, Dahut WL, Chen C, DiPaola RS, Stein MN, et al. A phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-tricom vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel. J Clin Oncol. 2013(Suppl 6): Abstract 102. doi:10.1200/jco.2013.31.6_suppl.102
   Google Scholar
• Heery CR, Madan RA, Stein MN, Stadler WM, Di Paola RS, Rauckhorst M, Steinberg SM, Marté JL, Chen CC, Grenga I, et al. Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial. Oncotarget. 2016;7(42):69014-023. doi:10.18632/oncotarget.10883. PMID:27486817
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264. doi:10.1038/nrc3239. PMID:22437870
   PubMed Web of Science ®Google Scholar
• Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009;206(8):1717-25. doi:10.1084/jem.20082492. PMID:19581407
   PubMed Web of Science ®Google Scholar
• Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700-712. doi:10.1016/S1470-2045(14)70189-5. PMID:24831977
   PubMed Web of Science ®Google Scholar
• Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, Ganju V, Polikoff J, Saad F, Humanski P, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017;35(1):40-47. doi:10.1200/JCO.2016.69.1584. PMID:28034081
   PubMed Web of Science ®Google Scholar
• Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: A phase 1 dose-escalation trial. Lancet Oncol. 2012;13(5):501-508. doi:10.1016/S1470-2045(12)70006-2. PMID:22326924
   PubMed Web of Science ®Google Scholar
• Jochems C, Tucker JA, Tsang KY, Madan RA, Dahut WL, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: Immune correlates. Cancer Immunol Immunother. 2014;63(4):407-418. doi:10.1007/s00262-014-1524-0. PMID:24514956
   PubMed Web of Science ®Google Scholar
• Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA Jr, Donehower RC, Jaffee EM, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother. 2013;36(7):382-389. doi:10.1097/CJI.0b013e31829fb7a2. PMID:23924790
   PubMed Web of Science ®Google Scholar
• Santegoets SJ, Stam AG, Lougheed SM, Gall H, Scholten PE, Reijm M, Jooss K, Sacks N, Hege K, Lowy I, et al. T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother. 2013;62(2):245-256. doi:10.1007/s00262-012-1330-5. PMID:22878899
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723. doi:10.1056/NEJMoa1003466. PMID:20525992
   PubMed Web of Science ®Google Scholar
• Wilgenhof S, Corthals J, Heirman C, van Baren N, Lucas S, Kvistborg P, Thielemans K, Neyns B. Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma. J Clin Oncol. 2016;34(12):1330-38. doi:10.1200/JCO.2015.63.4121. PMID:26926680
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521-32. doi:10.1056/NEJMoa1503093. PMID:25891173
   PubMed Web of Science ®Google Scholar
• Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908-918. doi:10.1016/S1470-2045(15)00083-2. PMID:26115796
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006-17. doi:10.1056/NEJMoa1414428. PMID:25891304
   PubMed Web of Science ®Google Scholar
• Daud A, Ribas A, Robert C, Stephen Hodi F, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, et al. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. ASCO; 2015;33(suppl 15):9005-05.
   Google Scholar
• Administration FaD. Hematology/Oncology (Cancer) approvals & Safety Notifications. 2017; https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm279174.htm. Accessed April 5, 2017.
   Google Scholar
• Karyampudi L, Lamichhane P, Scheid AD, Kalli KR, Shreeder B, Krempski JW, Behrens MD, Knutson KL. Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Res. 2014;74(11):2974-85. doi:10.1158/0008-5472.CAN-13-2564. PMID:24728077
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. 2017;5(1):3-8. doi:10.1158/2326-6066.CIR-16-0297. PMID:28052991
   PubMed Web of Science ®Google Scholar
• Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, Zhao X, Martinez AJ, Wang W, Gibney G, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013;31(34):4311-18. doi:10.1200/JCO.2013.51.4802. PMID:24145345
   PubMed Web of Science ®Google Scholar
• Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L, Eysmans C, Richards A, Schell MJ, Fisher KJ, et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res. 2015;21(4):712-720. doi:10.1158/1078-0432.CCR-14-2468. PMID:25524312
   PubMed Web of Science ®Google Scholar
• McNeel DG. DNA vaccine with pembrolizumab elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer (mCRPC). SITC. 2016; National Harbor, MD.
   Google Scholar
• Strbo N, Garcia-Soto A, Schreiber TH, Podack ER. Secreted heat shock protein gp96-Ig: Next-generation vaccines for cancer and infectious diseases. Immunol Res. 2013;57(1-3):311-325. doi:10.1007/s12026-013-8468-x. PMID:24254084
   PubMed Web of Science ®Google Scholar
• Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, Sherry RM, Royal RE, Steinberg SM, Rosenberg S. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: A retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 2008;113(2):293-301. doi:10.1002/cncr.23552. PMID:18457330
   PubMed Web of Science ®Google Scholar
• Gore ME, Larkin JM. Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br J Cancer. 2011;104(3):399-406. doi:10.1038/sj.bjc.6606084. PMID:21285971
   PubMed Web of Science ®Google Scholar
• Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21(16):3127-32. doi:10.1200/JCO.2003.02.122. PMID:12915604
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814-23. doi:10.1056/NEJMoa1510016. PMID:26406150
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Ren M, Dutcus C, Larkin J. Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lancet Oncol. 2016;17(1):e4-5. doi:10.1016/S1470-2045(15)00543-4. PMID:26758760
   PubMed Web of Science ®Google Scholar
• Ott PA, Adams S. Small-molecule protein kinase inhibitors and their effects on the immune system: Implications for cancer treatment. Immunotherapy. 2011;3(2):213-227. doi:10.2217/imt.10.99. PMID:21322760
   PubMed Web of Science ®Google Scholar
• Kwilas AR, Donahue RN, Tsang KY, Hodge JW. Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy. Cancer Cell Microenviron. 2015;2(1):e677. PMID:26005708
   PubMedGoogle Scholar
• Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, Wood L, Elson P, Garcia J, Dreicer R, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res. 2008;14(20):6674-82. doi:10.1158/1078-0432.CCR-07-5212. PMID:18927310
   PubMed Web of Science ®Google Scholar
• Zhao W, Gu YH, Song R, Qu BQ, Xu Q. Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation. Leukemia. 2008;22(6):1226-33. doi:10.1038/leu.2008.58. PMID:18337760
   PubMed Web of Science ®Google Scholar
• Farsaci B, Donahue RN, Coplin MA, Grenga I, Lepone LM, Molinolo AA, Hodge JW. Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines. Cancer Immunol Res. 2014;2(11):1090-1102. doi:10.1158/2326-6066.CIR-14-0076. PMID:25092771
   PubMed Web of Science ®Google Scholar
• Kwilas AR, Ardiani A, Donahue RN, Aftab DT, Hodge JW. Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. J Transl Med. 2014;12:294. doi:10.1186/s12967-014-0294-y. PMID:25388653
   PubMed Web of Science ®Google Scholar
• Amin A, Dudek AZ, Logan TF, Lance RS, Holzbeierlein JM, Knox JJ, Master VA, Pal SK, Miller WH Jr, Karsh LI, et al. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. J Immunother Cancer. 2015;3:14. doi:10.1186/s40425-015-0055-3. PMID:25901286
   PubMed Web of Science ®Google Scholar
• Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794-99. doi:10.1200/JCO.2008.21.4809. PMID:19826129
   PubMed Web of Science ®Google Scholar
• Hull EE, Montgomery MR, Leyva KJ. HDAC inhibitors as epigenetic regulators of the immune system: Impacts on cancer therapy and inflammatory diseases. Biomed Res Int. 2016;2016:8797206. doi:10.1155/2016/8797206. PMID:27556043
   PubMed Web of Science ®Google Scholar
• Gameiro SR, Malamas AS, Tsang KY, Ferrone S, Hodge JW. Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells. Oncotarget. 2016;7(7):7390-7402. doi:10.18632/oncotarget.7180. PMID:26862729
   PubMed Web of Science ®Google Scholar
• Lin KT, Wang YW, Chen CT, Ho CM, Su WH, Jou YS. HDAC inhibitors augmented cell migration and metastasis through induction of PKCs leading to identification of low toxicity modalities for combination cancer therapy. Clin Cancer Res. 2012;18(17):4691-4701. doi:10.1158/1078-0432.CCR-12-0633. PMID:22811583
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, Gitlitz B, Thomas S, Espinoza-Delgado I, Vokes EE, Gandara DR, et al. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(1):56-62. doi:10.1200/JCO.2009.24.9094. PMID:19933908
   PubMed Web of Science ®Google Scholar
• Generali D, Bates G, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, et al. Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clin Cancer Res. 2009;15(3):1046-51. doi:10.1158/1078-0432.CCR-08-1507. PMID:19188178
   PubMed Web of Science ®Google Scholar
• Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, Ellis TM, Wojcik EM, Yang D, Flanigan RC, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A. 2001;98(25):14565-570. doi:10.1073/pnas.251140998. PMID:11734652
   PubMed Web of Science ®Google Scholar
• Koh YT, Gray A, Higgins SA, Hubby B, Kast WM. Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate. 2009;69(6):571-584. doi:10.1002/pros.20906. PMID:19143030
   PubMed Web of Science ®Google Scholar
• Drake CG, Doody AD, Mihalyo MA, Huang CT, Kelleher E, Ravi S, Hipkiss EL, Flies DB, Kennedy EP, Long M, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell. 2005;7(3):239-249. doi:10.1016/j.ccr.2005.01.027. PMID:15766662
   PubMed Web of Science ®Google Scholar
• DiPaola RS, Chen YH, Bubley GJ, Stein MN, Hahn NM, Carducci MA, Lattime EC, Gulley JL, Arlen PM, Butterfield LH, et al. A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802. Eur Urol. 2015;68(3):365-371. doi:10.1016/j.eururo.2014.12.010. PMID:25533418
   PubMed Web of Science ®Google Scholar
• Madan RA, Gulley JL, Schlom J, Steinberg SM, Liewehr DJ, Dahut WL, Arlen PM. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res. 2008;14(14):4526-31. doi:10.1158/1078-0432.CCR-07-5048. PMID:18628467
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Kroemer G. Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects. J Clin Invest. 2009;119(8):2127-30. PMID:19620780
   PubMed Web of Science ®Google Scholar
• Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: Harnessing potential synergies. Cancer Immunol Res. 2015;3(5):436-443. doi:10.1158/2326-6066.CIR-15-0064. PMID:25941355
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28(6):690-714. doi:10.1016/j.ccell.2015.10.012. PMID:26678337
   PubMed Web of Science ®Google Scholar
• Shurin MR, Naiditch H, Gutkin DW, Umansky V, Shurin GV. Chemo immuno modulation: Immune regulation by the antineoplastic chemotherapeutic agents. Curr Med Chem. 2012;19(12):1792-1803. doi:10.2174/092986712800099785. PMID:22414087
   PubMed Web of Science ®Google Scholar
• Galetto A, Buttiglieri S, Forno S, Moro F, Mussa A, Matera L. Drug- and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells. Anticancer Drugs. 2003;14(10):833-843. doi:10.1097/00001813-200311000-00010. PMID:14597879
   PubMedGoogle Scholar
• Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, Frelinger JA, Robinson BW. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol. 2003;170(10):4905-13. doi:10.4049/jimmunol.170.10.4905. PMID:12734333
   PubMed Web of Science ®Google Scholar
• Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005;105(7):2862-68. doi:10.1182/blood-2004-06-2410. PMID:15591121
   PubMed Web of Science ®Google Scholar
• Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol. 2011;33(4):369-383. doi:10.1007/s00281-011-0245-0. PMID:21611872
   PubMed Web of Science ®Google Scholar
• Chen G, Gupta R, Petrik S, Laiko M, Leatherman JM, Asquith JM, Daphtary MM, Garrett-Mayer E, Davidson NE, Hirt K, et al. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. Cancer Immunol Res. 2014;2(10):949-961. doi:10.1158/2326-6066.CIR-14-0058. PMID:25116755
   PubMed Web of Science ®Google Scholar
• Huang CS, Yu AL, Tseng LM, et al. Randomized phase II/III trial of active immunotherapy with OPT-822/OPT-821 in patients with metastatic breast cancer. ASCO Annual Meeting. 2016;34(Suppl 15): Abstract 1003 (Presented June 4, 2016).
   Google Scholar
• Rettig L, Seidenberg S, Parvanova I, Samaras P, Curioni A, Knuth A, Pascolo S. Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells. Int J Cancer. 2011;129(4):832-838. doi:10.1002/ijc.25756. PMID:21710545
   PubMed Web of Science ®Google Scholar
• Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005;11(18):6713-21. doi:10.1158/1078-0432.CCR-05-0883. PMID:16166452
   PubMed Web of Science ®Google Scholar
• Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Nijman HW, van Poelgeest MI, van Erkel AR, Smit VT, Daemen TA, van der Hoeven JJ, et al. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget. 2015;6(31):32228-243. doi:10.18632/oncotarget.4772. PMID:26334096
   PubMed Web of Science ®Google Scholar
• Hardacre JM, Mulcahy M, Small W, Talamonti M, Obel J, Krishnamurthi S, Rocha-Lima CS, Safran H, Lenz HJ, Chiorean EG. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: A phase 2 study. J Gastrointest Surg. 2013;17(1):94-100; discussion p 100–101. doi:10.1007/s11605-012-2064-6. PMID:23229886
   PubMed Web of Science ®Google Scholar
• Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Kudrimoti MR, Fromm ML, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial. JAMA. 2008;299(9):1019-26. doi:10.1001/jama.299.9.1019. PMID:18319412
   PubMed Web of Science ®Google Scholar
• Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, Propper D, Coxon F, Ross P, Madhusudan S, Roques T, et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): An open-label, randomised, phase 3 trial. Lancet Oncol. 2014;15(8):829-840. doi:10.1016/S1470-2045(14)70236-0. PMID:24954781
   PubMed Web of Science ®Google Scholar
• Middleton G, Greenhalf W, Costello E, Shaw V, Cox T, Ghaneh P, Palmer DH, Neoptolemos JP. Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma. Br J Cancer. 2016;114(5):510-518. doi:10.1038/bjc.2015.468. PMID:26931369
   PubMed Web of Science ®Google Scholar
• Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: Effects of docetaxel on immune enhancement. Clin Cancer Res. 2008;14(11):3536-44. doi:10.1158/1078-0432.CCR-07-4025. PMID:18519787
   PubMed Web of Science ®Google Scholar
• Harrop R, Chu F, Gabrail N, Srinivas S, Blount D, Ferrari A. Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: A randomized phase II trial. Cancer Immunol Immunother. 2013;62(9):1511-20. doi:10.1007/s00262-013-1457-z. PMID:23877659
   PubMed Web of Science ®Google Scholar
• Rocha-Lima CM, de Queiroz Marques Junior E, Bayraktar S, Broome P, Weissman C, Nowacki M, Leslie M, Susnerwala S. A multicenter phase II study of G17DT immunogen plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan. Cancer Chemother Pharmacol. 2014;74(3):479-486. doi:10.1007/s00280-014-2520-y. PMID:25030089
   PubMed Web of Science ®Google Scholar
• Welters MJ, van der Sluis TC, van Meir H, Loof NM, van Ham VJ, van Duikeren S, Santegoets SJ, Arens R, de Kam ML, Cohen AF, et al. Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. Sci Transl Med. 2016;8(334):334ra352. doi:10.1126/scitranslmed.aad8307
   Web of Science ®Google Scholar
• Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z, Gervais R, Ottensmeier C, Szczesna A, Kazarnowicz A, et al. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. Lancet Oncol. 2016;17(2):212-223. doi:10.1016/S1470-2045(15)00483-0. PMID:26727163
   PubMed Web of Science ®Google Scholar
• Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, Koralewski P, Breton JL, Stoelben E, Braun D, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol. 2011;12(12):1125-33. doi:10.1016/S1470-2045(11)70259-5. PMID:22019520
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823-33. doi:10.1056/NEJMoa1606774. PMID:27718847
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909-20. doi:10.1016/S0140-6736(16)00561-4. PMID:26952546
   PubMed Web of Science ®Google Scholar
• Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, Amling CL, Stephenson RA, Simko J, Sheikh NA, et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst. 2014;106(11):dju268. doi:10.1093/jnci/dju268. PMID:25255802
   PubMedGoogle Scholar
• McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463-69. doi:10.1126/science.aaf1490. PMID:26940869
   PubMed Web of Science ®Google Scholar